June 2 (Reuters) - Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would ...

June 1 (Reuters) - Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised cancer-risk concerns, which ...

Fulcrum Therapeutics discontinues its pociredir program after the Food and Drug Administration raises concerns.

State Rep. Omari Crawford discusses a new Georgia law designed to expand oversight and improve access to care for people ...

A Silver Spring woman says for the first time in years, she’s feeling hopeful thanks to a groundbreaking therapy that’s ...

Fewer serious complications. Fewer hospitalizations and blood transfusions. Better growth and development. And a markedly ...

A Legacy of Equity gala in Chicago honors its commitment to advancing sickle cell research and care for children.

Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, ...

Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared ...

Chicagoans are invited to attend St. Jude Celebrates: A Legacy of Equity, a gala honoring St. Jude Children’s Research ...

Opinion editor’s note: Strib Voices publishes a mix of commentary online and in print each day. To contribute, click here. •• ...